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The consensus guideline development committee of Korean Society of Gynecologic Oncology was reconvened in March 2012. 
The committee consisted of 36 experts representing 12 university hospitals and professional organizations. The objective of 
this committee was to develop standardized guidelines for cervical cancer screening tests for Korean women and to distribute 
these guidelines to every clinician, eventually improving the quality of medical care. Since the establishment of the consensus 
guideline development committee, evidence-based guidelines have either been developed de novo considering specific 
Korean situations or by adaptation of preexisting consensus guidelines from other countries. Recommendations for cervical 
cancer screening tests, management of atypical squamous and glandular cells, and management of low-grade and high-grade 
squamous intraepithelial lesions were developed. Additionally, recommendations for human papillomavirus DNA testing and 
recommendations for adolescent and pregnant women with abnormal cervical screening test results were also included.
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INTRODUCTION
Unlike other gynecological cancers, cervical cancer has some 
distinct characteristics. First, sexual activity is strongly related 
to the development of this cancer. Second, cervical cancer 
is almost always preceded by precancerous lesions, namely, 
cervical intraepithelial neoplasias (CIN). Third, the precancer-
ous stage is quite long and ranges from 7 to 20 years, which 
enables early diagnosis at this stage [1]. Fourth, as compared 
with other organs, the cervix can be easily exposed using a 
speculum, which makes clinical procedures more feasible. 
Various screening guidelines for abnormal cervical cytology 
have been developed for the early diagnosis and treatment 
of precancerous lesions, and these guidelines are used 
worldwide [2-5]. However, most of the current guidelines 
were developed in the United States; thus, these guidelines 
may not be useful for Koreans. For example, the incidence of 
cervical cancer in Korea is much higher than that in Western 
countries, although it has been decreasing gradually over 
the past decade [6,7]. Moreover, the costs associated with 
the Papanicolaou (Pap) test, human papillomavirus (HPV) 
DNA test, and colposcopy are lower in Korea than that in the 
United States. Consequently, the development of Korean-
specific guidelines for cervical cancer screening is necessary.
GUIDELINE DEVELOPMENT PROCESS 
Since the reconvening of the consensus guideline develop-
ment committee in March 2012, numerous workshops 
and conferences have been held. Many experts, including 
gynecologic oncologists representing the Korean Society of 
Gynecologic Oncology, pathologists representing the Korean 
Society for Cytopathology, and statisticians working in preven-
tive medicine, were involved in this committee. The committee 
was further divided into the 5 subcommittees for the following 
themes: 1) cervical cancer screening tests, 2) atypical squa-
mous cells (ASC) and atypical glandular cells (AGC), 3) low-
grade squamous intraepithelial lesions (LSIL) and high-grade 
squamous intraepithelial lesions (HSIL), 4) HPV DNA tests, and 
5) special situations including those involving adolescent 
and pregnant women. Each subcommittee consisted of 1 
chairperson, 1 secretary, and 4-5 members.
The guidelines were developed based on preexisting 
guidelines developed by the American Society for Colposcopy 
and Cervical Pathology [2], the National Comprehensive Cancer 
Network [3], the United States Preventive Services Task Force 
[4], and the Institute for Clinical Systems Improvement [5]. 
Some guidelines were created de novo, whereas some were 
adaptations of the aforementioned guidelines. In either case, 
every effort was made to reflect specific situations in Korea, for 
example, the high incidence of cervical cancer, low medical 
costs, and distinct characteristics of the medical service systems. 
Each subcommittee created several key questions and 
performed a literature review to provide supporting evidence. 
Recommendations were then developed, revised, and ap-
proved through vigorous discussions among members at mul-
tiple workshops, small group meetings, and public hearings as 
well as through a web-based survey. Each recommendation 
was rated as “H (high),” “M (moderate),” “L (low),” “VL (very 
low),” or “E (expert consensus or lack of evidence)” according 
to the level of evidence [8,9]. Each recommendation was also 
rated as “S (strong)” or “W (weak)” following discussions among 
members of each subcommittee. In this paper, the ratings for 
each recommendation are provided as VLS, MS, etc. within 
parenthesis, where VLS stands for very low and strong, MS for 
moderate and strong, and so on.
The terminology used for this guideline adhered to the 2001 
Bethesda system. Abnormal morphology that may represent 
preinvasive squamous disease fell into 4 descriptive categories: 
ASC, AGC, LSIL, and HSIL. Clinical judgment should be used first 
when applying a guideline to an individual patient because 
the guideline may not reflect all situations.
CONSENSUS GUIDELINES
1. General screening guidelines
All women ≥20 years of age who have commenced sexual 
activities should undergo cervical cancer screening tests (VLS) 
[10-15]. In contrast, routine cervical cancer screening tests are 
not recommended for women under 20 years of age because 
despite the high incidence of HPV infection, spontaneous 
regression occurs frequently, and there is a very low incidence 
of invasive cervical cancer. Screening tests can however be 
performed when cervical cancer or preinvasive disease is sus-
pected. Cervical cancer screening tests can be discontinued in 
women ≥70 years old after 3 consecutive negative Pap tests 
within 10 years (ES). However, a woman should continue un-
dergoing screening tests regardless of age if she has a history 
of CIN grade 2 or greater or if she does not know her previous 
Pap test results. Considering the relatively high incidence of 
cervical cancer in Korea, easy access to the screening test, 
and relatively low medical cost, annual screening using the 
Pap test alone is recommended for 20-year-old to 70-year-
old women. However, a 3-year interval is recommended in 
Western countries (ES). 
According to the previous literature, liquid-based cytology 
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did not show improved sensitivity or specificity when com-
pared with conventional cytology [16-20]. However, the use 
of liquid-based cytology decreases the number of inadequate 
specimens. Considering the situation in Korea, either test 
can be chosen as a screening test (MS). A combination of 
cervical cytology and cervicography is not generally recom-
mended due to increased false-positive results and low cost-
effectiveness; however, this combination might be beneficial 
in terms of sensitivity (LW) [21-23]. 
Most newly acquired HPV infections regress spontaneously, 
and HPV DNA positivity decreases with age following a peak 
in adolescents and in women in their 20s [24]. Therefore, 
the HPV DNA test in combination with a cervical cytology 
test is recommended for women ≥30 years old (HS) [25-
43]. When both tests are negative, the screening interval 
can be extended to 2 years (HS). Although the prevalence of 
invasive cervical cancer and preinvasive diseases is expected 
to decrease due to vaccination, a change in the screening 
interval should be considered after more clinical data have ac-
cumulated (EW). A woman who has undergone hysterectomy 
should continue with screening tests if she has a history of 
CIN grade 2 or greater or if she does not know her previous 
cytology results (ES). 
2. Atypical squamous cells
ASC is further divided into ASC-undetermined significance 
(ASC-US) and ASC-cannot exclude a high grade squamous 
intraepithelial lesion (ASC-H). The risks of high-grade CIN and 
invasive cervical cancer are low in women with ASC-US versus 
those with ASC-H [44]. Excision or ablative therapies are not 
recommended for these patients in order to avoid potential 
overtreatment. Because of the high prevalence of CIN grades 
2 and 3 among women with ASC-H, the management of 
these patients is almost the same as that of patients with HSIL. 
1) Recommended management of women with ASC-US
Repeat cytological tests, a high-risk HPV DNA test, and an 
immediate colposcopy are all acceptable management strate-
gies for ≥20-year-old women with ASC-US (HS) [45-48]. When 
repeat cytology with a 6-month interval is chosen, colposcopy 
should be performed if the result of repeat cytology is ASC-US 
or greater [2]. After 2 consecutive “negative for intraepithelial 
lesion or malignancy” cytology results, the patient can return 
to routine screening. When an HPV DNA test is chosen for 
follow-up, a colposcopy should be performed if high-risk HPV 
is detected [2]. If immediate colposcopy is required and the 
colposcopy is satisfactory, the recommended management 
of women with CIN grade 1 or less is either an HPV DNA test 
at 12 months or repeat cytological tests at 6 and 12 months 
(MS) [49,50]. Women can return to routine screening after 2 
consecutive “negative for intraepithelial lesion or malignancy” 
cytology results 6 months apart or a negative HPV DNA test 
result at 12 months (ES). However, if CIN grade 2 or 3 is identi-
fied, a diagnostic excisional procedure should be performed. 
2) Recommended management of women with ASC-H
The recommended management of women with ASC-H 
is referral for a colposcopic examination [2]. A review of 
cytological, histological, and colposcopic findings can be 
performed if a colposcopy-directed biopsy did not indicate 
CIN grade 2 or greater (EW). Cervical cytology and colposcopy 
can be performed at 6-month intervals if a colposcopy-
directed biopsy did not indicate CIN grade 2 or greater (ES). 
These women can return to routine screening if 2 consecutive 
cytology and colposcopy results obtained 6 months apart are 
negative (ES). If CIN grade 2 or 3 is identified after colposcopy-
directed biopsy, a diagnostic excisional procedure should be 
performed.
3. Atypical glandular cells
Although AGC frequently arise due to benign conditions 
such as reactive cellular changes or polyps, they are associ-
ated with a clinically significant lesion (including CIN, cervical 
adenocarcinoma in situ [AIS], cervical cancer, and endometrial, 
ovarian, and fallopian tube cancers) in 45% of patients [2,51]. 
Previous studies have noted that 9%-38% of women with 
AGC have a clinically significant neoplasia such as CIN grade 
2 or 3, AIS, or cancer [2]. Gynecologic cancer is less common 
in women ≤35 years of age compared to women above 35 
years of age [2]. No single test has sufficient sensitivity to be 
utilized as an initial triage for women with AGC [52]. Therefore, 
multiple testing modalities should be used during the initial 
evaluation. 
1) Recommended management of women with AGC
For women with cytological AGC, an HPV DNA test, colpos-
copy, and endocervical curettage (ECC) are recommended 
(VLS) [44,53-56]. An endometrial biopsy is also recommended 
for women ≥35 years of age (VLS) [44,55,56]. However, it is only 
recommended for women <35 years of age if they have risk 
factors for endometrial cancer such as obesity, infertility, anovu-
lation, or polycystic ovarian syndrome; if they have undergone 
tamoxifen therapy; or if they have abnormal vaginal bleeding 
or atypical endometrial cells; or if they have family history of 
colorectal or endometrial cancer [3]. If colposcopy-directed 
biopsy and ECC identify CIN grades 1-3 or AIS, a diagnostic 
excisional procedure should be performed. However, women 
with satisfactory colposcopy results revealing CIN grade 1 and 
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negative ECC may be managed conservatively either with 
repeat cervical cytology every 6 months or with an HPV DNA 
test at 12 months. Colposcopy is recommended for women 
with a follow-up cytology indicating ASC-US or greater [3]. 
4. Low-grade squamous intraepithelial lesion
An LSIL is closely associated with a high risk of HPV infec-
tion. A recent meta-analysis showed that the overall HPV 
prevalence and the estimated HPV 16/18-positive fractions 
were 72.9% and 26.7%, respectively, in women with LSIL [57]. 
Based on colposcopy-directed biopsy, the rate of CIN grade 2, 
CIN grade 3, or cancer in women with LSIL was reported to be 
11%-14% [58,59]. 
1) Recommended management of women with LSIL
Colposcopy is recommended for women with LSIL (MS) [60]. 
The management of those with LSIL depends on whether 
the full transformation zone can be visualized by colposcopic 
examination, i.e., whether a satisfactory colposcopy can be 
achieved. ECC should be considered for patients in whom no 
lesions are identified and for those with an unsatisfactory col-
poscopy (with the exception of pregnant women) [2,3]. When 
CIN grade 2 or 3 is identified by ECC, excisional procedures 
should be performed. Repeat cervical cytology at 6 and 12 
months or an HPV DNA test at 12 months is recommended as 
follow-up management for patients in whom CIN grade 2 or 
3 is not detected by colposcopy-directed biopsy or in whom 
biopsy is not performed (ES). Excision or ablation is not recom-
mended for these women. A return to routine screening is 
recommended if 2 consecutive cervical cytological tests are 
negative for intraepithelial lesions or malignancies or if an HPV 
DNA test is negative during follow-up. Referral for colposcopy 
is recommended if ASC-US or greater is identified by follow-
up cytology or if an HPV DNA test is positive. If CIN grade 
2 or 3 is detected following colposcopy-directed biopsy, a 
diagnostic excisional procedure is recommended [2,3]. 
5. High-grade squamous intraepithelial lesion
Cytological HSIL is accompanied by a significant risk of high-
grade cervical disease or cancer. Histological CIN grade 2 or 
greater can be identified in 60%-70% of women with HSIL by 
colposcopy-directed biopsy, and CIN 2 or greater is diagnosed 
in 84%-97% of women who underwent a loop electrosurgical 
excision procedure [2,61]. Up to 18.8% of women with HSIL 
have invasive cervical cancer [62]. Therefore, follow-up of 
women with HSIL with an HPV DNA test or cervical cytology 
is inappropriate. Because colposcopy can miss a significant 
number of high-grade lesions, a majority of women will 
eventually undergo diagnostic excisional procedures [2].
1) Recommended management of women with HSIL
In cases of HSIL (with the exception of adolescent women), 
immediate diagnostic excisional procedures, including loop 
electrosurgical excision or conization, can be performed 
without colposcopic examination [63-65] (VLS). If colposcopic 
examination is elected, management of women with HSIL de-
pends on whether the colposcopic examination was satisfac-
tory or unsatisfactory. For those with a satisfactory colposcopy, 
management depends on whether the lesion was observable 
or not. When lesions cannot be visualized by colposcopy, 
ECC should be performed in women with no lesions or in 
those who have not undergone biopsy [3]. If ECC is negative, 
cytology and colposcopy should be repeated every 6 months 
until 2 consecutive negative results can be confirmed. If ECC 
is positive for CIN, diagnostic excisional procedures should be 
performed. When lesions are observable, 3 management op-
tions can be chosen if CIN grade 2 or greater is not identified 
following colposcopy-directed biopsy: diagnostic excisional 
procedures (VLS), review of cytological and histological 
specimens (ES), or observation with colposcopy and cytology 
at 6-month intervals for 1 year (ES). After 1 year of observation, 
women with 2 consecutive “negative for intraepithelial lesion 
or malignancy” cytological tests or negative colposcopy re-
sults can return to a routine screening program (ES). However, 
a diagnostic excisional procedure should be performed if the 
follow-up cytology shows HSIL. If CIN grade 2 or 3 is detected 
by colposcopy-directed biopsy at initial presentation, treat-
ment with an excisional procedure should be performed [66]. 
When the presence of residual disease at the resection margin 
after an excisional procedure cannot be determined, cervical 
cytology can be performed at 6 months or an HPV DNA test 
can be performed at 12 months (ES). 
6. HPV DNA test
Although cervical cytology has contributed to the early 
detection of CIN and cervical cancer, its shortcomings as a 
screening test (e.g., high false-negativity) are not negligible 
[67]. Moreover, because infection with high-risk HPV is now 
considered a necessary cause of cervical cancer, tests for high-
risk HPV have been proposed as adjuncts to cervical cytology 
tests. Evidence from previous literature indicates that the HPV 
DNA test has superior sensitivity for the detection of CIN grade 
2 or greater as compared with cervical cytology [17,68-73]. A 
Canadian randomized study comparing cervical cytology with 
the HPV DNA test in 9,667 women aged 30-69 years dem-
onstrated that the sensitivities of cervical cytology, the HPV 
DNA test, and both tests combined for the detection of CIN 
grade 2 or greater were 56.4%, 97.4%, and 100%, respectively 
[70], while their specificities were 97.3%, 94.3%, and 92.5%, 
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respectively. Women who are negative for both cytology and 
the HPV DNA test have a less than 1 in 1,000 risk of having CIN 
grade 2 or greater, and the risk of developing CIN grade 3 is 
very low [74,75]. 
An HPV DNA test can be performed as an adjunct test 
to cervical cytology in women aged 30 years and older to 
reduce the high false-negativity of cytology (HS) [68-73]. In 
addition to the Hybrid Capture 2 (HC2; Qiagen, Gaithersburg, 
MD, USA) test approved by the United States Food and Drug 
Administration, other HPV DNA detection methods including 
HPV DNA chip tests and polymerase chain reaction (PCR)-
based HPV detection kits are commonly used in Korea. These 
tests were comparable to the HC2 test with respect to their 
sensitivity and specificity for the detection of CIN grade 2 or 
greater and their concordance with HPV positivity [62,76-78]. 
Considering the specific situation in Korea and evidence from 
previous validation studies, HPV DNA chip tests and various 
PCR-based HPV detection kits can be used for the detection of 
HPV infection (LW) [76-79]. 
Many women in the screened populations who are positive 
for HPV infection show negative cervical cytology. The overall 
prevalence of HPV positivity was 6.5%, and 58% of HPV-
positive women had negative cytology [80]. Moreover, the 
risk of missing the diagnosis of CIN grade 2 or greater during 
routine screening is quite low (2.4%-5.1%) in women who are 
cytology-negative and HPV-positive [81,82]. It is important to 
determine which of these women are more likely to develop 
high-grade CIN or cancer. During a 10-year follow-up of 
cytology-negative, HPV-positive women ≥30 years of age, CIN 
grade 3 was detected in 21% and 18% of those carrying HPV 
16 and 18, respectively [75]. In contrast, the risk of CIN grade 
3 in women with other high-risk HPVs was only 1.5%. Based 
on these results, which indicate a differential risk of develop-
ing high-grade CIN depending on HPV genotype, an HPV 
genotyping test is recommended for cytology-negative, HPV-
positive women (LS) [74,75,83,84]. If HPV 16 or 18 is detected, 
referral to a gynecologic oncologist and a colposcopic exami-
nation are recommended (LS). In women who are positive 
for HPVs other than HPV 16 or 18, an HPV DNA test and HPV 
genotyping test can be performed 1 year later (LS).
7. Special situations
1) Management of adolescent women
The management of cervical abnormalities requires special 
consideration in adolescents and women younger than 20 
years of age. Previous studies indicate that the majority of 
young women will be infected with HPV within several years 
of commencement of sexual activities [69,85,86]. Because of 
the high prevalence of HPV and frequent regression in these 
women, routine HPV DNA testing is not recommended for 
those with cytological ASC-US or LSIL (LS) [86-88]. Instead, 
a regular follow-up with annual cytology is recommended. 
If cytology results at 12 months indicate HSIL or greater, the 
patient should be referred for colposcopy [2,3]. If cytology 
results at 24 months indicate ASC-US or greater, referral for 
colposcopy is also recommended [2,3]. 
Colposcopy is recommended if the initial cytology reveals 
ASC-H because of the increased risk of CIN grade 2 or greater 
[3]. When colposcopy is satisfactory, repeat cytology at 6 
months is recommended if CIN grade 2 or 3 is not identified. 
The patient can return to routine screening after 2 consecu-
tive negative cytology tests. However, colposcopy should be 
performed if cytology at 6 months reveals ASC-US or greater. 
When CIN grade 2 or 3 is identified, there are 2 management 
options: 1) excision or ablation, or 2) observation with cytol-
ogy and colposcopy every 6 months. Patients with unsatisfac-
tory colposcopy results should undergo ECC and cervical 
biopsy [3]. 
In adolescents with HSIL, colposcopy is recommended 
[2,3], although immediate excisional procedures are not. If 
histological CIN grade 2 or 3 is not identified, follow-up with 
cytology and colposcopy at 6-month intervals for up to 2 years 
is preferred. During follow-up, if a high-grade colposcopic 
lesion is identified or if HSIL persists for 1 year, biopsy should 
be performed. When HSIL persists for 24 months without 
identifiable CIN grade 2 or 3, excisional procedures should 
be performed. After 2 consecutive negative cytology results 
and no evidence of high-grade colposcopic abnormalities, 
adolescents can return to routine screening. When CIN grade 
2 or 3 is histologically confirmed, either excision/ablation or 
cytology and colposcopy every 6 months up to 24 months 
can be selected. Patients with unsatisfactory colposcopy 
results should undergo ECC and cervical biopsy [3]. 
2) Management of pregnant women
The management of nonadolescent pregnant women with 
ASC-US or LSIL is identical to that of nonpregnant women 
with ASC-US or LSIL. ECC is not permitted in pregnant 
women. Deferring the initial colposcopy until at least 6 weeks 
postpartum is a safe and acceptable management option 
for pregnant women with either ASC-US or LSIL (LS) [89,90]. 
Colposcopy is recommended for pregnant women with HSIL, 
and biopsy should be performed if high-grade CIN or cancer is 
suspected [2,3]. Among 78 women with histologically proven 
CIN grade 2 or 3, 48 (62%) showed disease regression during 
postpartum assessment [91]. No cases of invasive cancer were 
identified during follow-up. According to another prospective 
study on pregnant women with CIN grade 2 or 3 who were 
Cervical cancer screening guidelines
J Gynecol Oncol Vol. 24, No. 2:186-203 www.ejgo.org 191
followed-up with colposcopy and/or cytology, nearly half of 
the enrolled women showed regression of the initial disease, 
and none showed progression to invasive cancer [92]. If CIN 
grade 2 or 3 (but not invasive cancer) is identified histologi-
cally, diagnostic excisional procedures can be deferred until 
postpartum (LS). 
8. Follow-up after treatment of CIN with excisional proce-
dures or ablation
When ablative treatments such as laser therapy or 
cryotherapy are performed, the surgical margins cannot be 
assessed. In these cases, follow-up with cervical cytology at 6 
months or an HPV DNA test at 12 months is recommended 
[93]. Treatment of women initially managed with excisional 
procedures, such as the loop electrosurgical excisional pro-
cedure or conization, depends on the status of the resection 
margins. Cervical cytology at 6 months or an HPV DNA test at 
12 months is recommended for women with CIN grade 2 or 
3 with negative margins and for all women with CIN grade 1 
[3]. For women with CIN grade 2 or 3 with positive margins, 
3 options are available: 1) cervical cytology at 6 months, 2) 
ECC, or 3) re-excision if invasion is suspected or hysterectomy 
after a consultation with a specialist. If cervical cytology at 6 
months indicates ASC-US or greater, management should be 
performed as per the guidelines previously mentioned. For 
women with negative cytology results or a negative HPV DNA 
test, routine screening can be resumed. If an HPV DNA test 
is positive at 12 months, the patient should be referred for 
colposcopy.
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<Appendix A> Summary of recommendations 
*Full paper with evidence tables is available at ejgo.org.
1. General screening guideline
Recommendation 1 – When to start screening (adaptation)
All women ≥20 years of age that have commenced sexual 
intercourse should undergo cervical cancer screening tests. 
This is not recommended for women below the age of 20 
because despite the high incidence of HPV infection, there is a 
high rate of spontaneous regression and a very low incidence 
of invasive cervical cancer. However, the screening test can 
be performed when cervical cancer or preinvasive disease is 
suspected (Level of evidence: very low; Recommendation: 
strong).
Recommendation 2 – When to discontinue screening (expert 
consensus)
Cervical cancer screening tests can be discontinued in 
women ≥70 years old after 3 consecutive negative Pap tests 
within 10 years. However, a woman should continue undergo-
ing screening tests continuously regardless of age if she has a 
history of CIN 2 or greater or she does not know her previous 
Pap test results (Level of evidence: very low; Recommenda-
tion: strong).
Recommendation 3 – Screening interval (expert consensus)
Although the screening guidelines of Western countries 
recommend a 3-year interval, in Korea, annual screening with 
cervical cytology is recommended for women aged 20 to 70 
years due to the high incidence of cervical cancer, easy access 
to screening, and low medical costs (Level of evidence: very 
low; Recommendation: strong).
Recommendation 4 – Screening modality (conventional Pap 
versus liquid-based cytology) (adaptation)
Based on previous literature, liquid-based cytology is not 
superior to conventional cytology in terms of sensitivity and 
specificity; however, liquid-based cytology can reduce the 
number of inadequate specimens. Both liquid-based cytology 
and conventional cytology are usable in Korea (Level of 
evidence: moderate; Recommendation: strong).
Recommendation 5 – Cervicography as an adjunct to cytology 
(de novo)
The use of a combination of cervical cytology and cervicog-
raphy as a screening test is not commonly recommended 
due to increased false positivity. However, this combination 
may be beneficial in terms of improving sensitivity (Level of 
evidence: low; Recommendation: weak).
Recommendation 6 – HPV DNA test (adaptation)
Due to the high false-positivity rate of the test and the 
frequent spontaneous clearance of HPV, the HPV DNA test is 
not recommended for women <30 years of age. The screen-
ing interval can be extended to 2 years in women ≥30 years 
old with both a negative cytology and negative HPV (Level of 
evidence: high; Recommendation: strong).
Recommendation 7 – Screening interval (expert consensus)
Although the prevalence of invasive cervical cancer and pre-
invasive diseases is expected to decrease due to vaccination, 
a change in the screening interval should be considered after 
more clinical data have been accumulated (Level of evidence: 
very low; Recommendation: weak).
Recommendation 8 – Hysterectomized women (adaptation/
expert consensus)
Women who have undergone hysterectomy should con-
tinue with screening tests if they have a history of CIN grade 
2 or greater or if they do not know their previous cytology 
results (Level of evidence: very low; Recommendation: strong).
2. ASC/AGC
(1) ASC-US
Recommendation 1 (adaptation)
Repeat cytology can be performed for women with ASC-US 
(Level of evidence: high; Recommendation: strong).
Recommendation 2 (adaptation)
An HPV DNA test can be performed for women with ASC-US 
(Level of evidence: high; Recommendation: strong).
Recommendation 3 (adaptation)
Immediate colposcopy can be performed for women with 
ASC-US (Level of evidence: high; Recommendation: strong).
Recommendation 4 (adaptation)
When CIN grade 1 or less is confirmed after satisfactory 
colposcopy, either cytology at 6-month intervals or an HPV 
DNA test at 12 months is recommended (Level of evidence: 
moderate; Recommendation: strong).
Recommendation 5 (expert consensus)
After 2 consecutive negative cytologies 6 months apart or 
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a negative HPV DNA test at 12 months, women with ASC-US 
can return to routine screening (Level of evidence: very low; 
Recommendation: strong).
(2) ASC-H
Recommendation 1 (expert consensus)
When CIN grade 2 or greater is not confirmed by colposcopy-
directed biopsy in women with ASC-H, a review of the 
cytological and histological specimens can be performed (Level 
of evidence: very low; Recommendation: weak).
Recommendation 2 (expert consensus)
When CIN grade 2 or greater is not confirmed by colpos-
copy-directed biopsy in women with ASC-H, 2 consecutive 
cytology tests at 6-month intervals and colposcopy can be 
performed (Level of evidence: very low; Recommendation: 
strong).
Recommendation 3 (expert consensus)
When CIN grade 2 or greater is not confirmed by colposco-
py-directed biopsy in women with ASC-H, women can return 
to routine screening after 2 consecutive negative cytology 
tests at 6-month intervals and a negative colposcopy (Level of 
evidence: very low; Recommendation: strong).
(3) AGC
Recommendation 1 (adaptation)
An HPV DNA test is recommended for women with AGC 
(Level of evidence: very low; Recommendation: strong).
Recommendation 2 (adaptation)
Colposcopy, endocervical curettage, and endometrial biopsy 
should be performed in women with AGC (Level of evidence: 
very low; Recommendation: strong).
3. LSIL/HSIL
(1) LSIL
Recommendation 1 (adaptation)
Colposcopy is recommended for women with LSIL (Level of 
evidence: moderate; Recommendation: strong).
Recommendation 2 (expert consensus)
If 2 consecutive cytology tests 6 months apart are negative 
for intraepithelial neoplasia or if an HPV DNA test is negative 
at 12 months, women with LSIL can return to routine screen-
ing (Level of evidence: very low; Recommendation: strong).
(2) HSIL
Recommendation 1 (adaptation)
Immediate diagnostic excisional procedures, such as the 
loop electrosurgical excision procedure or conization, can be 
performed in women with HSIL without colposcopic examina-
tion (Level of evidence: very low; Recommendation: strong).
Recommendation 2 (adaptation)
Diagnostic excisional procedures can be performed in women 
with HSIL if CIN grade 2 or 3 is not identified by colposcopy-
directed biopsy (Level of evidence: very low; Recommendation: 
strong).
Recommendation 3 (expert consensus)
A review of cytological and histological specimens might be 
helpful in women with HSIL if CIN grade 2 or 3 is not identified 
by colposcopy-directed biopsy (Level of evidence: very low; 
Recommendation: strong).
Recommendation 4 (expert consensus)
When CIN grade 2 or 3 is not identified in women with HSIL 
by colposcopy-directed biopsy, follow-up with 2 cytology 
tests 6 months apart and colposcopy can be performed (Level 
of evidence: very low; Recommendation: strong).
Recommendation 5 (expert consensus)
When CIN 2 or 3 is not identified in women with HSIL by 
colposcopy-directed biopsy, they can return to routine 
screening if 2 consecutive cytology tests 6 months apart and 
colposcopy are negative (Level of evidence: very low; Recom-
mendation: strong).
Recommendation 6 (expert consensus)
When the margin status is not known after excisional 
procedures, either cytology at 6 months or an HPV DNA test 
at 12 months can be performed (Level of evidence: very low; 
Recommendation: strong).
4. HPV DNA tests
Recommendation 1 (adaptation)
An HPV DNA test can be performed in women ≥30 years old 
along with cervical cytology in order to reduce the false nega-
tivity of cytology (Level of evidence: high; Recommendation: 
strong).
Jae Kwan Lee, et al.
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<Appendix B> Flow charts of screening guidelines
1. Atypical glandular cells-undetermined significance
ASC-US, atypical squamous cells of undetermined significance; Bx, biopsy; CIN, cervical intraepithelial neoplasias; ECC, endocervical curettage; 
HPV, human papillomavirus, LEEP, loop electrosurgical excision procedure, Pap, Papanicolaou test. 
Recommendation 2 (de novo)
Use of the hybrid capture assay and HPV DNA genotyping 
test (HPV DNA chip, PCR test) is recommended because of 
their equivalent sensitivity and specificity for the detection of 
CIN grade 2 or greater as well as the concordance among vari-
ous HPV DNA tests (Level of evidence: low; Recommendation: 
weak).
Recommendation 3 (adaptation)
Use of the HPV genotyping test is recommended in 
cytology-negative, HPV-positive women. If HPV 16 or 18 is 
detected, referral to gynecologic oncologists and colposcopic 
examination are recommended. In women who are positive 
for HPVs other than 16 or 18, an HPV DNA test and HPV geno-
typing test can be performed 1 year later (Level of evidence: 
low; Recommendation: strong).
5. Special situations (adolescent/pregnant women)
Recommendation 1 (adaptation)
An HPV DNA test should not be performed in adolescent 
women with ASC-US or LSIL (Level of evidence: low; Recom-
mendation: strong).
Recommendation 2 (adaptation)
Postpartum colposcopy is safe for pregnant women with 
ASC-US or LSIL (Level of evidence: low; Recommendation: 
strong).
Recommendation 3 (adaptation)
Diagnostic excisional procedures can be deferred in 
pregnant women with histologically confirmed CIN grade 2 or 
greater (Level of evidence: low; Recommendation: strong).
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2. Atypical squamous cells-cannot exclude a high grade squamous intraepithelial lesion
3. Atypical glandular cells
Bx, biopsy; CIN, cervical intraepithelial neoplasias; ECC, endocervical curettage; LEEP, loop electrosurgical excision procedure; Pap, Papanicolaou 
test.
AIN, adenocarcinoma in situ; AGC, atypical glandular cells; NOS, not otherwise specified; CIN, cervical intraepithelial neoplasia; ECC, 
endocervical curettage; HPV, human papillomavirus; LEEP, loop electrosurgical excision procedure; Pap, Papanicolaou test.
(a) Endometrial biopsy can be omitted if the patients meet the criteria described below:
(1) <35 years of age, (2) low risk for endometrial cancer (i.e., no obesity, polycystic ovarian syndrome, tamoxifen usage, infertility, anovulation, 
or family history of colorectal or endometrial cancer), (3) no abnormal uterine bleeding, and (4) no atypical endometrial cells.
(b) Patients with CIN grade 1 limited to the endocervix can be followed up with cytology and an HPV DNA test.
(c) Conization is recommended if the lesion is located in the endocervix (or additional resection is recommended if LEEP was performed 
initially).
Jae Kwan Lee, et al.
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4. Low-grade squamous intraepithelial lesions
5. High-grade squamous intraepithelial lesions
ASC-US, atypical squamous cells of undetermined significance; Bx, biopsy; CIN, cervical intraepithelial neoplasia; ECC, endocervical curettage; 
HPV, human papillomavirus; LEEP, loop electrosurgical excision procedure; Pap, Papanicolaou test. 
Bx, biopsy; CIN, cervical intraepithelial neoplasia; ECC, endocervical curettage; HPV, human papillomavirus; LEEP, loop electrosurgical excision 
procedure; Pap, Papanicolaou test. 
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6. Follow-up after treatment of CIN with excisional procedures or ablation
7. Adolescents with ASC-US, LSIL, or ASC-H
ASC-US, atypical squamous cells of undetermined significance; CIN, cervical intraepithelial neoplasia; ECC, endocervical curettage; HPV, human 
papillomavirus; Pap, Papanicolaou test; RM, resection margin.
ASC-H, atypical squamous cells (cannot exclude a high-grade squamous intraepithelial lesion); ASC-US, atypical squamous cells of 
undetermined significance; Bx, biopsy; CIN, cervical intraepithelial neoplasia; ECC, endocervical curettage; HPV, human papillomavirus; HSIL, 
high-grade squamous intraepithelial lesion; LSIL, low-grade squamous intraepithelial lesion; Pap, Papanicolaou test. 
Jae Kwan Lee, et al.
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8. Adolescents with HSIL
9. Adolescents with CIN 1-3
CIN, cervical intraepithelial neoplasia; HSIL, high-grade squamous intraepithelial lesion; LEEP, loop electrosurgical excision procedure; Pap, 
Papanicolaou test. 
ASC-US, atypical squamous cells of undetermined significance; CIN, cervical intraepithelial neoplasia; HSIL, high-grade squamous intraepithelial 
lesion; Pap, Papanicolaou test; TZ, transformation zone. 
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10. Pregnant women with ASC-US
11. Pregnant women with LSIL or HSIL
ASC-US, atypical squamous cells of undetermined significance; CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus; Pap, 
Papanicolaou test.
CIN, cervical intraepithelial neoplasia; ECC, endocervical curettage; HSIL, high-grade squamous intraepithelial lesion; LEEP, loop electrosurgical 
excision procedure; LSIL, low-grade squamous intraepithelial lesion; R/O, rule out.
